Answers are grounded in this paper and cite their sources.
This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
No takes yet. Share an insight, caveat, or question.
Elshafie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: